Хроническая сердечная недостаточность с сохраненной фракцией выброса: возможно ли эффективное лечение?

Хроническая сердечная недостаточность с сохраненной фракцией выброса (ХСН-СФВ) левого желудочка составляет около 50% заболеваемости сердечной недостаточностью, однако фармакотерапия, улучшающая ее исходы, не разработана. Доказанным принципом улучшения исходов у больных с хронической сердечной недостаточностью со сниженной фракцией выброса левого желудочка является урежение частоты сердечных сокращений. В статье обсуждаются ситуации, в которых лечение ß-адреноблокаторами неэффективно или отрицательно влияет на исходы. Сопоставлены результаты собственного исследования и проекта EDIFY, в которых у больных с ХСН-СФВ применялся ивабрадин. Утверждается важность фенотипирования пациентов с ХСН-СФВ для повышения эффективности их лечения.

сердечная недостаточность с сохраненной фракцией выброса, ß-адреноблокаторы, ивабрадин, диастолическая дисфункция левого желудочка, chronic heart failure with preserved ejection fraction, ß-bIockers, ivabradine, left ventricular diastolic dysfunction

1. Ponikowski P., Voors A. A., Anker S. D. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: he Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37: 2129-2200.

2. Dunlay S. M., Roger V. L., Redfield M. M. Epidemiology of heart failure with preserved ejection fraction. Nat Rev Cardiol 2017; 14: 591-602.

3. Chioncel O., Lainscak M., Seferovic P. M. et al. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 2017; 19: 1574-1585.

4. Tschöpe C., Van Linthout S., Kherad B. Heart Failure with Preserved Ejection Fraction and Future Pharmacological Strategies: a Glance in the Crystal Ball. Curr Cardiol Rep 2017; 19: 70.

5. Pieske B., Maggioni A. P., Lam C. S. P. et al. Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study. Eur Heart J 2017; 38: 1119-1127.

6. Zamani P., Akers S., Soto-Calderon H. et al. Isosorbide Dinitrate, With or Without Hydralazine, Does Not Reduce Wave Reflections, Left Ventricular Hypertrophy, or Myocardial Fibrosis in Patients With Heart Failure With Preserved Ejection Fraction. J Am Heart Assoc 2017; 6 (2) pii: e004262.

7. Kotecha D., Flather M. D., Altman D. G. et al. Beta-Blockers in Heart Failure Collaborative Group. Heart Rate and Rhythm and the Benefit of Beta-Blockers in Patients With Heart Failure. J Am Coll Cardiol 2017; 69: 2885-2896.

8. Dondo T. B., Hall M., West R. M. et al. ß-Blockers and Mortality After Acute Myocardial Infarction in Patients Without Heart Failure or Ventricular Dysfunction. J. Am Coll Cardiol 2017; 69: 2710-2720.

9. Ibanez B., Raposeiras-Roubin S., Garcia-Ruiz J. M. The Swing of b-blockers: Time for a System Reboot. J. Am Coll Cardiol 2017; 69: 2721-2724.

10. Tsujimoto T., Sugiyama T., Shapiro M. F. et al. Risk of Cardiovascular Events in Patients With Diabetes Mellitus on ß-Blockers. Hypertension 2017; 70: 103-110.

11. Castagno D., Skali H., Takeuchi M. et al. Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program. J. Am Coll Cardiol 2012; 59: 1785-1795.

12. Bohm M., Perez A. C., Jhund P. S. et al. Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve). Eur J. Heart Fail 2014; 16: 778-787.

13. Swedberg K., Komajda M., Bohm M. et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebocontrolled study. Lancet 2010; 376: 875-885.

14. Tardif J. C., O'Meara E., Komajda M. et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. Eur Heart J. 2011; 32: 2507-2515.

15. Канорский С. Г., Борисенко Ю. В. Сравнительная оценка ß-адреноблокатора и ингибитора If-каналов у больных с сохраненной фракцией выброса левого желудочка. Кардиология 2016; 56 (2): 24-29

16. Komajda M., Isnard R., Cohen-Solal A. et al. prEserveD left ventricular ejectIon fraction chronic heart Failure with ivabradine studY (EDIFY) Investigators. Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial. Eur J. Heart Fail 2017; 19: 1495-1503.

17. Busseuil D., Shi Y., Mecteau M. et al. Heart rate reduction by ivabradine reduces diastolic dysfunction and cardiac fibrosis. Cardiology 2010; 117: 234-242.

18. Reil J. C., Hohl M., Reil G. H. et al. Heart rate reduction by If-inhibition improves vascular stiffness and left ventricular systolic and diastolic function in a mouse model of heart failure with preserved ejection fraction. Eur Heart J. 2013; 34: 2839-2849.

19. Kosmala W., Holland D.J., Rojek A. et al. Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial. J. Am Coll Cardiol 2013; 62: 1330-1338.

20. Pal N., Sivaswamy N., Mahmod M. et al. Effect of selective heart rate slowing in heart failure with preserved ejection fraction. Circulation 2015; 132: 1719-1725.

21. Shah S.J., Katz D. H., Selvaraj S. et al. Phenomapping for novel classification of heart failure with preserved ejection fraction. Circulation 2015; 131: 269-279.

22. Shah S. J., Kitzman D. W., Borlaug B. A. et al. Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap. Circulation 2016; 134: 73-90.

23. Samson R., Jaiswal A., Ennezat P. V. et al. Clinical Phenotypes in Heart Failure With Preserved Ejection Fraction. J. Am Heart Assoc 2016; 5 (1).

24. Pitt B., Pfeffer M. A., Assmann S. F. et al.; TOPCAT Investigators. Spironolactone for heart failure with preserved ejection fraction. N. Engl J. Med 2014; 370: 1383-1392.

25. Pfeffer M. A., Claggett B., Assmann S. F. et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation 2015; 131: 34-42.

26. Yancy C. W., Jessup M., Bozkurt B. et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation 2017; 136: e137-e161.

27. Furuhashi T., Moroi M. Cardiovascular prognosis in patients with preserved left ventricular ejection fraction and no significant ischemia. Res Rep Clin Cardiol 2017; 8: 41-48.

28. Tsioufis C., Georgiopoulos G., Oikonomou D. et al. Hypertension and heart failure with preserved ejection fraction: connecting the dots. Curr Vasc Pharmacol 2017; 16: 15-22.

29. Katz D. H., Deo R. C., Aguilar F. G. et al. Phenomapping for the Identification of Hypertensive Patients with the Myocardial Substrate for Heart Failure with Preserved Ejection Fraction. J. Cardiovasc Transl Res 2017; 10: 275-284.

30. O'Neal W. T., Sandesara P. B., Samman-Tahhan A. et al. Heart rate and the risk of adverse outcomes in patients with heart failure with preserved ejection fraction. Eur J. Prev Cardiol 2017; 24: 1212-1219.

31. Thorup L., Simonsen U., Grimm D., Hedegaard E. R. Ivabradine: Current and Future Treatment of Heart Failure. Basic Clin Pharmacol Toxicol 2017; 121: 89-97.